Precigen PGEN is scheduled to report third-quarter 2026 earnings on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $75.4 million, while the same for earnings is pinned at 9 cents per share.
Let’s see how things might have shaped up before the announcement.
Factors Likely to Influence PGEN's Q3 Results
Precigen’s revenues are likely to have been driven by strong sales of its sole marketed drug, Papzimeos (zopapogene imadenovec-drba), during the third quarter. Papzimeos is an FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). The drug has witnessed strong commercial momentum since its approval and launch.
Product revenues from Papzimeos more than doubled sequentially during the second quarter of 2026. It remains to be seen whether the same trend continued in the to-be-reported quarter.
A marketing authorization application, seeking approval for Papzimeos to treat adults with RRP, is currently under review in Europe. A potential approval in Europe could further boost the drug’s sales and drive revenues. Management can provide an update on the timeline for the approval on the upcoming investor call.
Year to date, shares of Precigen have surged 66.1% compared with the industry’s increase of 11.3%.
Image Source: Zacks Investment Research
Beyond Papzimeos, Precigen retains pipeline potential through its AdenoVerse platform. The company is developing PRGN-2009, an investigational AdenoVerse immunotherapy in mid-stage studies for HPV-driven cancers. The FDA recently granted platform technology designation to Precigen’s AdenoVerse immunotherapeutic platform.
Investors will be keen to get more clinical and regulatory updates on the company's pipeline progress on the upcoming call.
Potential Competition Ails PGEN’s Stock
Last week, the FDA granted accelerated approval to Inovio Pharmaceuticals’ INO Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd), previously known as INO-3107, to reduce the frequency of surgery in adults with RRP.
The FDA approval on Oct. 30 reportedly weighed on investor sentiment toward Precigen’s Papzimeos, sending its shares plunging around 20% as investors assessed the potential competitive threat from INO’s Voceryq.
Inovio expects to begin making Voceryq available for ordering and shipment in approximately 60 days, with a full commercial launch planned for the first quarter of 2027.
PGEN's Earnings Surprise History
Precigen has a mixed earnings-surprise history. The company beat earnings estimates in three of the trailing four quarters and missed in the remaining one, delivering an average surprise of 108.96%. In the last reported quarter, PGEN posted an earnings surprise of 350.00%.
Precigen, Inc. Price and EPS Surprise
Precigen, Inc. price-eps-surprise | Precigen, Inc. Quote
Earnings Whispers for PGEN
Our proven model does not conclusively predict an earnings beat for Precigen this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Earnings ESP: Precigen’s Earnings ESP is -7.69% as the Most Accurate Estimate stands at 8 cents per share, lower than the Zacks Consensus Estimate of 9 cents.
Zacks Rank: PGEN has a Zacks Rank #3 at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks to Consider
Here are two drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Amneal Pharmaceuticals AMRX has an Earnings ESP of +4.17% and a Zacks Rank #2.
Amneal’s stock has surged 70.7% so far this year. AMRX beat estimates in each of the last four quarters. The company has a four-quarter earnings surprise of 32.82%, on average. Amneal is scheduled to report third-quarter results on Nov. 3.
Pfizer PFE has an Earnings ESP of +3.53% and a Zacks Rank #3 at present.
Shares of Pfizer have risen 28.9% so far this year. Pfizer beat earnings estimates in each of the last four reported quarters, delivering an average earnings surprise of 16.62%. Pfizer is scheduled to report third-quarter results on Nov. 3.
Radical New Technology Could Hand Investors Huge Gains
Quantum Computing is the next technological revolution, and it could be even more advanced than AI.
While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.
Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power .
Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.
See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Precigen, Inc. (PGEN): Free Stock Analysis Report
Pfizer Inc. (PFE): Free Stock Analysis Report
Inovio Pharmaceuticals, Inc. (INO): Free Stock Analysis Report
AMNEAL PHARMACEUTICALS, INC. (AMRX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).